Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 5,004 shares at $68.00 ($342K) on 2026-06-22, disclosed to the SEC on 2026-06-24.
Scheduled sale ($342k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.00 | 2,808 | $191K | 55.9% |
| 2 | $68.57 | 2,196 | $151K | 44.1% |
| Total | $68.25 avg | 5,004 | $342K | 100% |
| Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |
| BBIO | SELL | 2025-11-14 | $3.4M | — | Filing → |